onr:"swepub:oai:lup.lub.lu.se:13ac1eec-6fa4-4afc-9e1d-507fb2f4366b"
Search: onr:"swepub:oai:lup.lub.lu.se:13ac1eec-6fa4-4afc-9e1d-507fb2f4366b" > Calcineurin Inhibit...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Ekberg, HenrikLund University,Lunds universitet,Enheten för forskning kring njurfunktion och njursjukdom,Kirurgi,Forskargrupper vid Lunds universitet,Renal Research Unit,Surgery,Lund University Research Groups (author)
Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation.
- Article/chapterEnglish2009
Publisher, publication year, extent ...
- Elsevier BV,2009
Numbers
- LIBRIS-ID:oai:lup.lub.lu.se:13ac1eec-6fa4-4afc-9e1d-507fb2f4366b
- https://lup.lub.lu.se/record/1453535URI
- https://doi.org/10.1111/j.1600-6143.2009.02726.xDOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- The Symphony study showed that at 1 year posttransplant, a regimen based on daclizumab induction, 2 g mycophenolate mofetil (MMF), low-dose tacrolimus and steroids resulted in better renal function and lower acute rejection and graft loss rates compared with three other regimens: two with low-doses of cyclosporine or sirolimus instead of tacrolimus and one with no induction and standard cyclosporine dosage. This is an observational follow-up for 2 additional years with the same endpoints as the core study. Overall, 958 patients participated in the follow-up. During the study, many patients changed their immunosuppressive regimen (e.g. switched from sirolimus to tacrolimus), but the vast majority (95%) remained on MMF. During the follow-up, renal function remained stable (mean change: -0.6 ml/min), and rates of death, graft loss and acute rejection were low (all about 1% per year). The MMF and low-dose tacrolimus arm continued to have the highest GFR (68.6 +/- 23.8 ml/min vs. 65.9 +/- 26.2 ml/min in the standard-dose cyclosporine, 64.0 +/- 23.1 ml/min in the low-dose cyclosporine and 65.3 +/- 26.2 ml/min in the low-dose sirolimus arm), but the difference with the other arms was not significant (p = 0.17 in an overall test and 0.077, 0.039 and 0.11, respectively, in pair-wise tests). The MMF and low-dose tacrolimus arm also had the highest graft survival rate, but with reduced differences between groups over time, and the least acute rejection rate. In the Symphony study, the largest ever prospective study in de novo kidney transplantation, over 3 years, daclizumab induction, MMF, steroids and low-dose tacrolimus proved highly efficacious, without the negative effects on renal function commonly reported for standard CNI regimens.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Bernasconi, C (author)
- Tedesco-Silva, H (author)
- Vítko, S (author)
- Hugo, C (author)
- Demirbas, A (author)
- Reyes Acevedo, R (author)
- Grinyó, J (author)
- Frei, U (author)
- Vanrenterghem, Y (author)
- Daloze, P (author)
- Halloran, P (author)
- Enheten för forskning kring njurfunktion och njursjukdomKirurgi (creator_code:org_t)
Related titles
- In:American Journal of Transplantation: Elsevier BV9, s. 1876-18851600-6135
Internet link
Find in a library
- American Journal of Transplantation (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Ekberg, Henrik
- Bernasconi, C
- Tedesco-Silva, H
- Vítko, S
- Hugo, C
- Demirbas, A
- show more...
- Reyes Acevedo, R
- Grinyó, J
- Frei, U
- Vanrenterghem, Y
- Daloze, P
- Halloran, P
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Surgery
- Articles in the publication
- American Journal ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
